-
1
-
-
0023913120
-
The steroid and thyroid hormone receptor superfamily
-
Evans RM (1988) The steroid and thyroid hormone receptor superfamily. Science 240:889-895
-
(1988)
Science
, vol.240
, pp. 889-895
-
-
Evans, R.M.1
-
2
-
-
0024545638
-
Gene regulation by steroid hormones
-
Beato M (1989) Gene regulation by steroid hormones. Cell 56: 335-344
-
(1989)
Cell
, vol.56
, pp. 335-344
-
-
Beato, M.1
-
3
-
-
0029618368
-
Steroid hormone receptor: Many actors in search of a plot
-
Beato M, Herrlich P, Schütz, G (1995) Steroid hormone receptor: many actors in search of a plot. Cell 83:851-857
-
(1995)
Cell
, vol.83
, pp. 851-857
-
-
Beato, M.1
Herrlich, P.2
Schütz, G.3
-
4
-
-
0028283503
-
Molecular mechanisms of action of steroid/thyroid hormone receptor superfamily members
-
Tsui M-J, O'Malley BW (1994) Molecular mechanisms of action of steroid/thyroid hormone receptor superfamily members. Ann Rev Biochem 63:451-486
-
(1994)
Ann Rev Biochem
, vol.63
, pp. 451-486
-
-
Tsui, M.-J.1
O'Malley, B.W.2
-
6
-
-
0019993591
-
Effect d'un steroid antiprogesterone chez, la femme interruption du cycle menstruel de la grosseese au debut
-
Herrman W, Wyss R, Rinodel A, Philibert D, Teutsch G, Sakiz E, Baulieu E (1982) Effect d'un steroid antiprogesterone chez, la femme interruption du cycle menstruel de la grosseese au debut. CR Acad Sci 294:933-938
-
(1982)
CR Acad Sci
, vol.294
, pp. 933-938
-
-
Herrman, W.1
Wyss, R.2
Rinodel, A.3
Philibert, D.4
Teutsch, G.5
Sakiz, E.6
Baulieu, E.7
-
7
-
-
0024470651
-
Contragestion and other clinical applications of RU 486, an antiprogesterone at the receptor
-
Baulieu E (1989) Contragestion and other clinical applications of RU 486, an antiprogesterone at the receptor. Science 245: 1351-1357
-
(1989)
Science
, vol.245
, pp. 1351-1357
-
-
Baulieu, E.1
-
9
-
-
0027296395
-
Mifepristone (RU 486) - A modulator of progestin and glucocorticoid action
-
Spitz IM, Bardin CW (1993) Mifepristone (RU 486) - a modulator of progestin and glucocorticoid action. N Engl J Med 329:404-412
-
(1993)
N Engl J Med
, vol.329
, pp. 404-412
-
-
Spitz, I.M.1
Bardin, C.W.2
-
10
-
-
0027525305
-
Clinical pharmacology of RU 486 - An antiprogestin and antiglucocorticoid
-
Spitz IM, Bardin CW (1993) Clinical pharmacology of RU 486 - an antiprogestin and antiglucocorticoid. Contraception 48:403-144
-
(1993)
Contraception
, vol.48
, pp. 403-1144
-
-
Spitz, I.M.1
Bardin, C.W.2
-
12
-
-
0028124826
-
Effect of the antiprogestin onapristone on follicular growth in women
-
Croxatto HB, Salvatierra AM, Fuentealba B, Zurth C, Beier S (1994) Effect of the antiprogestin onapristone on follicular growth in women. Hum Reprod 9:1442-1447
-
(1994)
Hum Reprod
, vol.9
, pp. 1442-1447
-
-
Croxatto, H.B.1
Salvatierra, A.M.2
Fuentealba, B.3
Zurth, C.4
Beier, S.5
-
13
-
-
0028040033
-
Termination of early pregnancy with ZK 98,734:pharmacokinetic behavior and clinical effect
-
Swahn M-L, Kovacs E, Cekan SZ, Aedo A-A, Westlund P (1994) Termination of early pregnancy with ZK 98,734:pharmacokinetic behavior and clinical effect. Hum Reprod 9:57-63
-
(1994)
Hum Reprod
, vol.9
, pp. 57-63
-
-
Swahn, M.-L.1
Kovacs, E.2
Cekan, S.Z.3
Aedo, A.-A.4
Westlund, P.5
-
14
-
-
0023571530
-
Disruption of follicular maturation and delay of ovulation after administration of the antiprogesterone RU 486
-
Liu JH, Garzo G, Morris S, Stuenkel CA, Ulman A, Yen SSC (1987) Disruption of follicular maturation and delay of ovulation after administration of the antiprogesterone RU 486. J Clin Endocrinol Metab 65:1135-1140
-
(1987)
J Clin Endocrinol Metab
, vol.65
, pp. 1135-1140
-
-
Liu, J.H.1
Garzo, G.2
Morris, S.3
Stuenkel, C.A.4
Ulman, A.5
Yen, S.S.C.6
-
15
-
-
0023579662
-
Effects of the antiprogesterone RU 486 in normal women. II. Administration in the late follicular phase
-
Shoupe D, Mishell DJ, Page MA, Madkour H, Spitz IM, Lobo RA (1987) Effects of the antiprogesterone RU 486 in normal women. II. Administration in the late follicular phase. Am J Obstet Gynecol 157:1421-1426
-
(1987)
Am J Obstet Gynecol
, vol.157
, pp. 1421-1426
-
-
Shoupe, D.1
Mishell, D.J.2
Page, M.A.3
Madkour, H.4
Spitz, I.M.5
Lobo, R.A.6
-
16
-
-
0023914163
-
Inhibition of folliculogenesis and ovulation by the antiprogesterone RU 486
-
Luukkainen T, Heikinheimo O (1988) Inhibition of folliculogenesis and ovulation by the antiprogesterone RU 486. Fertil Steril 49:961-963
-
(1988)
Fertil Steril
, vol.49
, pp. 961-963
-
-
Luukkainen, T.1
Heikinheimo, O.2
-
17
-
-
0026717896
-
Interruption of endometrial maturation without hormonal changes by an antiprogesterone during the first half of the luteal phase of the menstrual cycle: A contraceptive potential
-
Greene KE, Kettel EM, Yen SSC (1992) Interruption of endometrial maturation without hormonal changes by an antiprogesterone during the first half of the luteal phase of the menstrual cycle: a contraceptive potential. Fertil Steril 58:338-343
-
(1992)
Fertil Steril
, vol.58
, pp. 338-343
-
-
Greene, K.E.1
Kettel, E.M.2
Yen, S.S.C.3
-
18
-
-
0027481262
-
Effects of continuous treatment with low dose mifepristone throughout one menstrual cycle
-
Croxatto H, Salvatierra AM, Fuentealba B (1993) Effects of continuous treatment with low dose mifepristone throughout one menstrual cycle. Hum Reprod 8:201-207
-
(1993)
Hum Reprod
, vol.8
, pp. 201-207
-
-
Croxatto, H.1
Salvatierra, A.M.2
Fuentealba, B.3
-
19
-
-
0026695314
-
Delayed endometrial maturation induced by daily administration of the antiprogestin RU486: A potential new contraceptive strategy
-
Batista M, Cartledge T, Zellnier A, Merino M, Axiotis C, Loriaux E, Nieman E (1992) Delayed endometrial maturation induced by daily administration of the antiprogestin RU486: a potential new contraceptive strategy. Am J Obstet Gynecol 167:60-65
-
(1992)
Am J Obstet Gynecol
, vol.167
, pp. 60-65
-
-
Batista, M.1
Cartledge, T.2
Zellnier, A.3
Merino, M.4
Axiotis, C.5
Loriaux, E.6
Nieman, E.7
-
20
-
-
0027200597
-
Treatment with a progesterone antagonist ZK 98,299 delays endometrial development without blocking ovulation in bonnet monkeys
-
Ishward P, Katkam R, Hinduja I, Chwalisz K, Elger W, Puri C (1993) Treatment with a progesterone antagonist ZK 98,299 delays endometrial development without blocking ovulation in bonnet monkeys. Contraception 48:57-70
-
(1993)
Contraception
, vol.48
, pp. 57-70
-
-
Ishward, P.1
Katkam, R.2
Hinduja, I.3
Chwalisz, K.4
Elger, W.5
Puri, C.6
-
21
-
-
0024791247
-
Noneompetitive antiestrogenic effect of RU 486 in blocking the estrogen-stimulated luteinizing hormone surge and the proliferative action of estradiol on endometrium in castrated monkeys
-
Wolf JP, Hsiu J, Anderson T, Ulmann A, Baulieu EE, Hodgen G (1989) Noneompetitive antiestrogenic effect of RU 486 in blocking the estrogen-stimulated luteinizing hormone surge and the proliferative action of estradiol on endometrium in castrated monkeys. Fertil Steril 52:1055-1060
-
(1989)
Fertil Steril
, vol.52
, pp. 1055-1060
-
-
Wolf, J.P.1
Hsiu, J.2
Anderson, T.3
Ulmann, A.4
Baulieu, E.E.5
Hodgen, G.6
-
22
-
-
0025917499
-
Inhibition of the estradiol-mediated endometrial gland formation by the antigestagen onapristone in rabbits: Relationship to uterine estroszen receptors
-
Chwalisz K, Hegele-Hartung C, Fritzemeier K-H, Beier HM, Elger W (1991) Inhibition of the estradiol-mediated endometrial gland formation by the antigestagen onapristone in rabbits: relationship to uterine estroszen receptors. Endocrinology 129:312-322
-
(1991)
Endocrinology
, vol.129
, pp. 312-322
-
-
Chwalisz, K.1
Hegele-Hartung, C.2
Fritzemeier, K.-H.3
Beier, H.M.4
Elger, W.5
-
23
-
-
0030032480
-
Treatment of endometriosis with the antiprogesterone mifepristone (RU486)
-
Kettel LM, Murphy AA, Morales AJ, Ulmann A, Baulieu EE, Yen SSC (1996) Treatment of endometriosis with the antiprogesterone mifepristone (RU486). Fertil Steril 65:23-28
-
(1996)
Fertil Steril
, vol.65
, pp. 23-28
-
-
Kettel, L.M.1
Murphy, A.A.2
Morales, A.J.3
Ulmann, A.4
Baulieu, E.E.5
Yen, S.S.C.6
-
24
-
-
0027467445
-
Regression of uterine leiomyomata in response to the anti-progesterone RU486
-
Murphy A, Kettel M, Morales A, Roberts V, Yen S (1993) Regression of uterine leiomyomata in response to the anti-progesterone RU486. J Clin Endocr Metab 76:513-517
-
(1993)
J Clin Endocr Metab
, vol.76
, pp. 513-517
-
-
Murphy, A.1
Kettel, M.2
Morales, A.3
Roberts, V.4
Yen, S.5
-
25
-
-
0023263044
-
The antiprogestin RU 486 in advanced breast cancer: Preliminary clinical trail
-
Romieu G, Maudelonde T, Ulmann A, Pujol H, Caval G, Khalaf S, Rochefort H (1987) The antiprogestin RU 486 in advanced breast cancer: preliminary clinical trail. Bull Cancer 74:455-461
-
(1987)
Bull Cancer
, vol.74
, pp. 455-461
-
-
Romieu, G.1
Maudelonde, T.2
Ulmann, A.3
Pujol, H.4
Caval, G.5
Khalaf, S.6
Rochefort, H.7
-
26
-
-
0024319047
-
Antiprogestins, a new form of endocrine therapy for human breast cancer
-
Klijn JAGM, de Jong FH, Bakker GH, Lamberts SWJ, Rodenburg CJ, Alexieva-Eigusch J (1989) Antiprogestins, a new form of endocrine therapy for human breast cancer. Cancer Res 49:2851-2856
-
(1989)
Cancer Res
, vol.49
, pp. 2851-2856
-
-
Klijn, J.A.G.M.1
De Jong, F.H.2
Bakker, G.H.3
Lamberts, S.W.J.4
Rodenburg, C.J.5
Alexieva-Eigusch, J.6
-
27
-
-
7144238535
-
Onapristone, a progesterone receptor antagonist, as first line endocrine therapy in primary breast cancer
-
poster 515
-
Robertson, JFR, Wilhser P, Blamey RW (1996) Onapristone, a progesterone receptor antagonist, as first line endocrine therapy in primary breast cancer (poster 515). In: 19th Annual San Antonio Breast Cancer Symposium
-
(1996)
19th Annual San Antonio Breast Cancer Symposium
-
-
Robertson, J.F.R.1
Wilhser, P.2
Blamey, R.W.3
-
28
-
-
0025884486
-
Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone
-
Grunberg SM, Weiss MH, Spitz IM, Ahmadi J, Sadun A, Russell CA, Lucci E, Stevenson EL (1991) Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. J Neurosurg 74:861-866
-
(1991)
J Neurosurg
, vol.74
, pp. 861-866
-
-
Grunberg, S.M.1
Weiss, M.H.2
Spitz, I.M.3
Ahmadi, J.4
Sadun, A.5
Russell, C.A.6
Lucci, E.7
Stevenson, E.L.8
-
29
-
-
0025239785
-
Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B
-
Kastner P, Krust A, Turcotte B, Stropp U, Tora L, Gronemeyer H, Chambon P (1990) Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J 9:1603-1614
-
(1990)
EMBO J
, vol.9
, pp. 1603-1614
-
-
Kastner, P.1
Krust, A.2
Turcotte, B.3
Stropp, U.4
Tora, L.5
Gronemeyer, H.6
Chambon, P.7
-
30
-
-
0023545241
-
The A and B forms of the chicken progesterone receptor arise by alternate initiation of translation of a unique mRNA
-
Conneely OM, Maxwell BE, Toft DO, Schrader WT, O'Malley BW (1987) The A and B forms of the chicken progesterone receptor arise by alternate initiation of translation of a unique mRNA. Biochem Biophys Res Commun 149:493-501
-
(1987)
Biochem Biophys Res Commun
, vol.149
, pp. 493-501
-
-
Conneely, O.M.1
Maxwell, B.E.2
Toft, D.O.3
Schrader, W.T.4
O'Malley, B.W.5
-
31
-
-
0027494065
-
Antagonist-occupied human progesterone B-receptors activate transcription without binding to progesterone response elements and are dominantly inhibited by A-receptors
-
Tung L, Mohamed MK, Hoeffler JP, Takimoto GS, Horwitz KB (1993) Antagonist-occupied human progesterone B-receptors activate transcription without binding to progesterone response elements and are dominantly inhibited by A-receptors. Mol Endocrinol 7:1256-1265
-
(1993)
Mol Endocrinol
, vol.7
, pp. 1256-1265
-
-
Tung, L.1
Mohamed, M.K.2
Hoeffler, J.P.3
Takimoto, G.S.4
Horwitz, K.B.5
-
32
-
-
0027427216
-
Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function
-
Vegeto E, Shahbaz MM, Wen DX, Goldman ME, O'Malley BW, McDonnell DP (1993) Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function. Mol Endoerinol 7:1244-55
-
(1993)
Mol Endoerinol
, vol.7
, pp. 1244-1255
-
-
Vegeto, E.1
Shahbaz, M.M.2
Wen, D.X.3
Goldman, M.E.4
O'Malley, B.W.5
McDonnell, D.P.6
-
33
-
-
0027081043
-
Ligand-dependent conformational changes in the progesterone receptor are necessary for events that follow DNA binding
-
Allan GE, Tsai SY, Tsai M-J, O'Malley BW (1992) Ligand-dependent conformational changes in the progesterone receptor are necessary for events that follow DNA binding. Proc Natl Acad Sci USA 89:11750-11754
-
(1992)
Proc Natl Acad Sci USA
, vol.89
, pp. 11750-11754
-
-
Allan, G.E.1
Tsai, S.Y.2
Tsai, M.-J.3
O'Malley, B.W.4
-
34
-
-
0026653659
-
The mechanism of RU486 antagonism is dependent on the conformation of the carboxy-terminal tail of the human progesterone receptor
-
Vegeto E, Allan GF, Schrader WT, Tsai M-J, McDonnell DP, O'Malley BW (1992) The mechanism of RU486 antagonism is dependent on the conformation of the carboxy-terminal tail of the human progesterone receptor. Cell 69:703-713
-
(1992)
Cell
, vol.69
, pp. 703-713
-
-
Vegeto, E.1
Allan, G.F.2
Schrader, W.T.3
Tsai, M.-J.4
McDonnell, D.P.5
O'Malley, B.W.6
-
35
-
-
0026786105
-
Ligands induce conformational changes in the carboxyl-terminus of progesterone receptors which are detected by a site-directed antipeptide monoclonal antibody
-
Weigel NL, Beck CA, Estes PA, Prendergast P, Altmann M, Christensen K, Edwards DP (1992) Ligands induce conformational changes in the carboxyl-terminus of progesterone receptors which are detected by a site-directed antipeptide monoclonal antibody. Mol Endocrinol 6:1585-1597
-
(1992)
Mol Endocrinol
, vol.6
, pp. 1585-1597
-
-
Weigel, N.L.1
Beck, C.A.2
Estes, P.A.3
Prendergast, P.4
Altmann, M.5
Christensen, K.6
Edwards, D.P.7
-
36
-
-
0029026914
-
Definition of the critical cellular components which distinguish between hormone and antihormone activated progesterone receptor
-
Clemm DL, Macy BL, Santiso-Mere D, McDonnell DP (1995) Definition of the critical cellular components which distinguish between hormone and antihormone activated progesterone receptor. J Steroid Biochem Mol Biol 53:487-495
-
(1995)
J Steroid Biochem Mol Biol
, vol.53
, pp. 487-495
-
-
Clemm, D.L.1
Macy, B.L.2
Santiso-Mere, D.3
McDonnell, D.P.4
-
37
-
-
0026512047
-
A single amino acid that determines the sensitivity of progesterone receptors to RU486
-
Benhamou B, Garcia T, Lerouge T, Vergezac A, Gofflo D, Bigogne C, Chambon P, Gronemeyer H (1992) A single amino acid that determines the sensitivity of progesterone receptors to RU486. Science 255:206-209
-
(1992)
Science
, vol.255
, pp. 206-209
-
-
Benhamou, B.1
Garcia, T.2
Lerouge, T.3
Vergezac, A.4
Gofflo, D.5
Bigogne, C.6
Chambon, P.7
Gronemeyer, H.8
-
38
-
-
0029757966
-
16 Alpha-substituted analogs of the antiprogestin RU486 induce a unique conformation in the human progesterone receptor resulting in mixed agonist activity
-
Wagner BL, Pollio G, Leonhardt S, Wani MC, Lee DY, Imhof MO, Edwards DP, Cook CE, McDonnell DP (1996) 16 Alpha-substituted analogs of the antiprogestin RU486 induce a unique conformation in the human progesterone receptor resulting in mixed agonist activity. Proc Natl Acad Sci USA 93: 8739-8744
-
(1996)
Proc Natl Acad Sci USA
, vol.93
, pp. 8739-8744
-
-
Wagner, B.L.1
Pollio, G.2
Leonhardt, S.3
Wani, M.C.4
Lee, D.Y.5
Imhof, M.O.6
Edwards, D.P.7
Cook, C.E.8
McDonnell, D.P.9
-
39
-
-
0027231954
-
Type II antagonists impair the DNA binding of steroid hormone receptors without affecting dimerization
-
Bocquel MT, Ji J, Ylikomi T, Benhamou B, Vergezac A, Chambon P, Gronemeyer H. (1993) Type II antagonists impair the DNA binding of steroid hormone receptors without affecting dimerization. J Steroid Biochem Mol Biol 45:205-215
-
(1993)
J Steroid Biochem Mol Biol
, vol.45
, pp. 205-215
-
-
Bocquel, M.T.1
Ji, J.2
Ylikomi, T.3
Benhamou, B.4
Vergezac, A.5
Chambon, P.6
Gronemeyer, H.7
-
40
-
-
0029023839
-
Progesterone receptor and the mechanism of action of progesterone antagonists
-
Edwards DP, Altmann M, DeMarzo A, Zhang Y, Weigel NL, Beck CA (1995) Progesterone receptor and the mechanism of action of progesterone antagonists. J Steroid Mol Biol 53: 449-458
-
(1995)
J Steroid Mol Biol
, vol.53
, pp. 449-458
-
-
Edwards, D.P.1
Altmann, M.2
DeMarzo, A.3
Zhang, Y.4
Weigel, N.L.5
Beck, C.A.6
-
41
-
-
0021610642
-
New steroids with antiprogestational and antiglucocorticoid activities
-
Neef G, Beier S, Elger W, Henderson D; Wiechert R (1984) New steroids with antiprogestational and antiglucocorticoid activities. Steroids 44:349-372
-
(1984)
Steroids
, vol.44
, pp. 349-372
-
-
Neef, G.1
Beier, S.2
Elger, W.3
Henderson, D.4
Wiechert, R.5
-
42
-
-
0026096890
-
Two types of antiprogestines identified by their differential action in transcriptionally active extracts from T47D cells
-
Klein-Hitpass L, Cato ACB, Henderson D, Ryffel GU (1991) Two types of antiprogestines identified by their differential action in transcriptionally active extracts from T47D cells. Nucleic Acids Res 19:1227-1233
-
(1991)
Nucleic Acids Res
, vol.19
, pp. 1227-1233
-
-
Klein-Hitpass, L.1
Cato, A.C.B.2
Henderson, D.3
Ryffel, G.U.4
-
43
-
-
0000539648
-
Regulation of progesterone receptor activity in cell culture systems and cell-free transcription
-
Fusenig NE, Graf H (eds) Springer, Berlin Heidelberg New York
-
Vaßen L, Klotzbücher M, Ulber V, Ryffel GU, Klein-Hitpass L (1994) Regulation of progesterone receptor activity in cell culture systems and cell-free transcription. In: Fusenig NE, Graf H (eds) Cell culture in pharmaceutical research. Proceedings of the Schering Research Foundation, vol 11. Springer, Berlin Heidelberg New York, pp 267-297
-
(1994)
Cell Culture in Pharmaceutical Research. Proceedings of the Schering Research Foundation
, vol.11
, pp. 267-297
-
-
Vaßen, L.1
Klotzbücher, M.2
Ulber, V.3
Ryffel, G.U.4
Klein-Hitpass, L.5
-
44
-
-
0027231954
-
Type II antagonists impair the DNA binding of steroid hormone receptors without affecting dimerization
-
Bocquel MT, Ji J, Ylikomi T, Benhamou B, Vergezac A, Chambon P, Gronemeyer H (1993) Type II antagonists impair the DNA binding of steroid hormone receptors without affecting dimerization. J Steroid Biochem Mol Biol 45: 205-215
-
(1993)
J Steroid Biochem Mol Biol
, vol.45
, pp. 205-215
-
-
Bocquel, M.T.1
Ji, J.2
Ylikomi, T.3
Benhamou, B.4
Vergezac, A.5
Chambon, P.6
Gronemeyer, H.7
-
45
-
-
0029147690
-
Mechanism of action of antiprogestins in the pregnant uterus
-
Henderson D, Philibert D, Roy AK, Teutsch G (eds) Dallas USA
-
Chwalisz K, Stöckemann K, Fuhrmann U, Fritzemeier KH, Einspanier A, Garfield RE (1995) Mechanism of action of antiprogestins in the pregnant uterus. In: Henderson D, Philibert D, Roy AK, Teutsch G (eds) Annuals of the New York Academy of Science: steroid receptors and antihormones. IX International Congress on Hormonal Steroid, Dallas USA, pp S202-224
-
(1995)
Annuals of the New York Academy of Science: Steroid Receptors and Antihormones. IX International Congress on Hormonal Steroid
-
-
Chwalisz, K.1
Stöckemann, K.2
Fuhrmann, U.3
Fritzemeier, K.H.4
Einspanier, A.5
Garfield, R.E.6
-
46
-
-
0024434594
-
Human progesterone receptor complexed with the antagonist RU 486 binds to hormone response elements in a structurally altered form
-
El-Ashry D, Onate SA, Nordeen SK, Edwards DP (1990) Human progesterone receptor complexed with the antagonist RU 486 binds to hormone response elements in a structurally altered form. Mol Endocrinol 3:1545-1558
-
(1990)
Mol Endocrinol
, vol.3
, pp. 1545-1558
-
-
El-Ashry, D.1
Onate, S.A.2
Nordeen, S.K.3
Edwards, D.P.4
-
47
-
-
0027195589
-
In vivo evidence against the existence of antiprogestines disrupting receptor binding to DNA
-
Delabre K, Guichon-Mantel A, Milgrom E (1993) In vivo evidence against the existence of antiprogestines disrupting receptor binding to DNA. Proc Natl Acad Sci USA 90:4421-4425
-
(1993)
Proc Natl Acad Sci USA
, vol.90
, pp. 4421-4425
-
-
Delabre, K.1
Guichon-Mantel, A.2
Milgrom, E.3
-
48
-
-
0028052137
-
Antiprogestines prevent progesterone receptor binding to hormone responsive elements in vivo
-
Truss M, Bartsch J, Beato M (1994) Antiprogestines prevent progesterone receptor binding to hormone responsive elements in vivo. Proc Natl Acad Sci USA 91:11333-11337
-
(1994)
Proc Natl Acad Sci USA
, vol.91
, pp. 11333-11337
-
-
Truss, M.1
Bartsch, J.2
Beato, M.3
-
49
-
-
0029168036
-
Identification of a group of Ser-Pro motif hormone-inducible phosphorylation sites in the human progesterone receptor
-
Zhang Y, Beck CA, Poletti A, Edwards DP, Weigel NL (1995) Identification of a group of Ser-Pro motif hormone-inducible phosphorylation sites in the human progesterone receptor. Mol Endocrinol 9:1029-1040
-
(1995)
Mol Endocrinol
, vol.9
, pp. 1029-1040
-
-
Zhang, Y.1
Beck, C.A.2
Poletti, A.3
Edwards, D.P.4
Weigel, N.L.5
-
50
-
-
0024508880
-
Phosphotryptic peptide analysis of human progesterone receptors
-
Sheridan PL, Evans RM, Horwitz KB (1989) Phosphotryptic peptide analysis of human progesterone receptors. J Biol Chem 264:6520-6528
-
(1989)
J Biol Chem
, vol.264
, pp. 6520-6528
-
-
Sheridan, P.L.1
Evans, R.M.2
Horwitz, K.B.3
-
51
-
-
0028305348
-
Multiple signaling pathways activate the chicken progesterone receptor
-
Zhang Y, Bai W, Allgood VE, Weigel NL (1994) Multiple signaling pathways activate the chicken progesterone receptor. Mol Endocrinol 8:577-584
-
(1994)
Mol Endocrinol
, vol.8
, pp. 577-584
-
-
Zhang, Y.1
Bai, W.2
Allgood, V.E.3
Weigel, N.L.4
-
52
-
-
0026559680
-
Hormone-induced progesterone receptor phosphorylation consists of sequential DNA-independent and DNA-dependent stages: Analysis with zinc finger mutants and the progesterone antagonist ZK98299
-
Takimoto GS, Tasset DM, Eppert AC, Horwitz KB (1992) Hormone-induced progesterone receptor phosphorylation consists of sequential DNA-independent and DNA-dependent stages: analysis with zinc finger mutants and the progesterone antagonist ZK98299. Proc Natl Acad Sci USA 89: 3050-3054
-
(1992)
Proc Natl Acad Sci USA
, vol.89
, pp. 3050-3054
-
-
Takimoto, G.S.1
Tasset, D.M.2
Eppert, A.C.3
Horwitz, K.B.4
-
53
-
-
0030052297
-
Two types of anti-progestins have distinct effects on site-specific phosphorylation of human progesterone receptor
-
Beck CA, Zhang Y, Weigel NL, Edwards DP (1996) Two types of anti-progestins have distinct effects on site-specific phosphorylation of human progesterone receptor. J Biol Chem 271:1209-1217
-
(1996)
J Biol Chem
, vol.271
, pp. 1209-1217
-
-
Beck, C.A.1
Zhang, Y.2
Weigel, N.L.3
Edwards, D.P.4
-
54
-
-
0027191140
-
The progesterone antagonist RU486 acquires agonist activity upon stimulation of cAMP signaling pathways Proc
-
Beck CA, Weigel NL, Mover ML, Nordeen SK, Edwards DP (1992) The progesterone antagonist RU486 acquires agonist activity upon stimulation of cAMP signaling pathways Proc Natl Acad Sci USA 90:4441-4445
-
(1992)
Natl Acad Sci USA
, vol.90
, pp. 4441-4445
-
-
Beck, C.A.1
Weigel, N.L.2
Mover, M.L.3
Nordeen, S.K.4
Edwards, D.P.5
-
55
-
-
0027156480
-
Antagonist-occupied human progesterone receptors hound to DNA are functionally switched to transcriptional agonists by cAMP
-
Sartorius CA, Tung L, Takimoto GS, Horwitz KB (1993) Antagonist-occupied human progesterone receptors hound to DNA are functionally switched to transcriptional agonists by cAMP. J Biol Chem 268:9262-9266
-
(1993)
J Biol Chem
, vol.268
, pp. 9262-9266
-
-
Sartorius, C.A.1
Tung, L.2
Takimoto, G.S.3
Horwitz, K.B.4
-
56
-
-
0028026693
-
New T47D breast cancer cell lines for the independent study of progesterone B- and A-receptors: Only antiprogestin-occupied B-receptors are switched to transcriptional agonists by cAMP
-
Sartorius CA, Groshong SD, Miller LA, Powell RL, Tung L, Takimoto GS, Horwitz KB (1994) New T47D breast cancer cell lines for the independent study of progesterone B- and A-receptors: only antiprogestin-occupied B-receptors are switched to transcriptional agonists by cAMP. Cancer Res 54:3868-3877
-
(1994)
Cancer Res
, vol.54
, pp. 3868-3877
-
-
Sartorius, C.A.1
Groshong, S.D.2
Miller, L.A.3
Powell, R.L.4
Tung, L.5
Takimoto, G.S.6
Horwitz, K.B.7
-
57
-
-
0021931574
-
Endometrial and pituitary responses to the steroidal antiprogestin RU486 in postmenopausal women
-
Gravanis A, Schaison G, George M (1985) Endometrial and pituitary responses to the steroidal antiprogestin RU486 in postmenopausal women. J. Clin Endocr Metab 60:156-163
-
(1985)
J. Clin Endocr Metab
, vol.60
, pp. 156-163
-
-
Gravanis, A.1
Schaison, G.2
George, M.3
-
58
-
-
0024811660
-
The antitumor mechanism of progesterone antagonists is a receptor mediated antiproliferative effect by induction of terminal cell death
-
Michna H, Schneider MR, Nishino Y, El Etreby MF (1989) The antitumor mechanism of progesterone antagonists is a receptor mediated antiproliferative effect by induction of terminal cell death. J Steroid Biochem 34:447-453
-
(1989)
J Steroid Biochem
, vol.34
, pp. 447-453
-
-
Michna, H.1
Schneider, M.R.2
Nishino, Y.3
El Etreby, M.F.4
-
59
-
-
7144233948
-
Antitumor activity and mechanism of action of the progesterone antagonist in experimental breast cancer
-
Masobrio M, Menato G, Cassoni P, Simonetta M (eds) Moduzzi, Bologna
-
Schneider MR, Michna H, Nishino Y, Henderson D (1991) Antitumor activity and mechanism of action of the progesterone antagonist in experimental breast cancer In: Masobrio M, Menato G, Cassoni P, Simonetta M (eds) Attualita endocrine in oncologia ginecologica e in medicina del riproduzione. Moduzzi, Bologna, pp 90-105
-
(1991)
Attualita Endocrine in Oncologia Ginecologica e in Medicina del Riproduzione
, pp. 90-105
-
-
Schneider, M.R.1
Michna, H.2
Nishino, Y.3
Henderson, D.4
-
60
-
-
0026636999
-
The molecular biology of RU486. Is there a role for antiprogestins in the treatment of breast cancer?
-
Horwitz KB (1992) The molecular biology of RU486. Is there a role for antiprogestins in the treatment of breast cancer? Endocr Rev 13:146-163
-
(1992)
Endocr Rev
, vol.13
, pp. 146-163
-
-
Horwitz, K.B.1
-
62
-
-
0027527240
-
Effects of the progestin antagonist RU 486 on T-47D cell cycle kinetics and cell cycle regulatory genes
-
Musgrove EA, Sutherland RL (1993) Effects of the progestin antagonist RU 486 on T-47D cell cycle kinetics and cell cycle regulatory genes. Biochem Biophys Res Commun 195: 1184-1190
-
(1993)
Biochem Biophys Res Commun
, vol.195
, pp. 1184-1190
-
-
Musgrove, E.A.1
Sutherland, R.L.2
-
63
-
-
0027299883
-
Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression
-
Musgrove E, Hamilton J, Lee C, Sweeny K, Watts C, Sutherland R (1993) Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Mol Cel Biol 13:3577-3587
-
(1993)
Mol Cel Biol
, vol.13
, pp. 3577-3587
-
-
Musgrove, E.1
Hamilton, J.2
Lee, C.3
Sweeny, K.4
Watts, C.5
Sutherland, R.6
-
64
-
-
0031032142
-
Antiprogestin inhibition of cell cycle progression in T-47D breast cancer cells is accompanied by induction of the cyclin-dependent kinase inhibitor p21
-
Musgrove, EA, Lee CSL, Cornish AL, Swarbrick A, Sutherland RL (1997) Antiprogestin inhibition of cell cycle progression in T-47D breast cancer cells is accompanied by induction of the cyclin-dependent kinase inhibitor p21. Mol Endocrinol 11:54-66
-
(1997)
Mol Endocrinol
, vol.11
, pp. 54-66
-
-
Musgrove, E.A.1
Lee, C.S.L.2
Cornish, A.L.3
Swarbrick, A.4
Sutherland, R.L.5
-
65
-
-
0030268048
-
Endometrial effects of RU 486 in primates-antiproliferative action and increased cyclin-B expression
-
Heikinheimo O, Hsiu J-G, Gordon K, Kim S, Williams RF, William EG, Hodgen GD (1996) Endometrial effects of RU 486 in primates-antiproliferative action and increased cyclin-B expression. J Steroid Biochem 59:179-190
-
(1996)
J Steroid Biochem
, vol.59
, pp. 179-190
-
-
Heikinheimo, O.1
Hsiu, J.-G.2
Gordon, K.3
Kim, S.4
Williams, R.F.5
William, E.G.6
Hodgen, G.D.7
-
66
-
-
0025062215
-
Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen
-
Berry M, Metzger D, Chambon P (1990) Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO J 9:2811-2818
-
(1990)
EMBO J
, vol.9
, pp. 2811-2818
-
-
Berry, M.1
Metzger, D.2
Chambon, P.3
-
67
-
-
0005520886
-
Tamoxifen as an agonist for metastatic breast cancer
-
Goldhirsch A (ed) Springer. Berlin Heidelberg New York
-
Howell A, Dodwell DJ, Laidlaw I, Anderson H, Anderson E (1990) Tamoxifen as an agonist for metastatic breast cancer. In: Goldhirsch A (ed) Endocrine therapy of breast cancer. Springer. Berlin Heidelberg New York, pp 49-58
-
(1990)
Endocrine Therapy of Breast Cancer
, pp. 49-58
-
-
Howell, A.1
Dodwell, D.J.2
Laidlaw, I.3
Anderson, H.4
Anderson, E.5
-
68
-
-
0003193675
-
Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy
-
Early Breast Cancer Trialists' Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet 339:1-15
-
(1992)
Lancet
, vol.339
, pp. 1-15
-
-
-
69
-
-
0019478633
-
Clinical aspects and development of anti-estrogen therapy: A review of the endocrine effects of tamoxifen in animals and man
-
Patterson JS (1981) Clinical aspects and development of anti-estrogen therapy: a review of the endocrine effects of tamoxifen in animals and man. J Endocrinol 89:323-329
-
(1981)
J Endocrinol
, vol.89
, pp. 323-329
-
-
Patterson, J.S.1
-
70
-
-
0027412216
-
High grade endometrial carcinoma in tamoxifen treated breast cancer patients
-
Magriples A, Naftolin F, Scharz PE (1993) High grade endometrial carcinoma in tamoxifen treated breast cancer patients. J Clin Oncol 11:485-490
-
(1993)
J Clin Oncol
, vol.11
, pp. 485-490
-
-
Magriples, A.1
Naftolin, F.2
Scharz, P.E.3
-
72
-
-
0026395885
-
A potent specific pure antiestrogen with clinical potential
-
Wakeling AE, Dukes M, Bowler J (1991) A potent specific pure antiestrogen with clinical potential. Cancer Res 51:3867-3873
-
(1991)
Cancer Res
, vol.51
, pp. 3867-3873
-
-
Wakeling, A.E.1
Dukes, M.2
Bowler, J.3
-
73
-
-
0028267672
-
RU 58 668, a new pure antiestrogen inducing a regression of human mammary carcinoma implanted in nude mice
-
Van de Velde P, Nique F, Bouchoux F, Brémaud J, Hameau M-C, Lucas D, Moratille C, Viel S, Philibert D, Teutsch G (1994) RU 58 668, a new pure antiestrogen inducing a regression of human mammary carcinoma implanted in nude mice. J Steroid Biochem Mol Biol 48:187-196
-
(1994)
J Steroid Biochem Mol Biol
, vol.48
, pp. 187-196
-
-
Van De Velde, P.1
Nique, F.2
Bouchoux, F.3
Brémaud, J.4
Hameau, M.-C.5
Lucas, D.6
Moratille, C.7
Viel, S.8
Philibert, D.9
Teutsch, G.10
-
75
-
-
0026556306
-
Coupling of dual signalling pathways: Epidermal growth factor action involves the estrogens receptor
-
Ignar-Trowbridge DM, Nelson KG, Bidwell MC, Curtis SW, Washburn TF, McLachlan JA, Korach K (1992) Coupling of dual signalling pathways: epidermal growth factor action involves the estrogens receptor. Proc Natl Acad Sci USA 89: 4658-1662
-
(1992)
Proc Natl Acad Sci USA
, vol.89
, pp. 4658-11662
-
-
Ignar-Trowbridge, D.M.1
Nelson, K.G.2
Bidwell, M.C.3
Curtis, S.W.4
Washburn, T.F.5
McLachlan, J.A.6
Korach, K.7
-
76
-
-
0029078487
-
Antiestrogens: Mechanisms and actions in target cells
-
Katzenellenbogen BS, Montano MM, Le Goff P, Schodin DJ, Lee Kraus W, Bhardwaj B, Fujimoto N (1995) Antiestrogens: mechanisms and actions in target cells. J Steroid Biochem. Mol Biol 53:387-393
-
(1995)
J Steroid Biochem. Mol Biol
, vol.53
, pp. 387-393
-
-
Katzenellenbogen, B.S.1
Montano, M.M.2
Le Goff, P.3
Schodin, D.J.4
Lee Kraus, W.5
Bhardwaj, B.6
Fujimoto, N.7
-
77
-
-
0029877913
-
Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation
-
Bunone G, Briand P-A, Miksicek J, Picard D (1996) Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J 15:2174-2183
-
(1996)
EMBO J
, vol.15
, pp. 2174-2183
-
-
Bunone, G.1
Briand, P.-A.2
Miksicek, J.3
Picard, D.4
-
78
-
-
0028886694
-
Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase
-
Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, Metzger D, Chambon, P (1995) Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270:1491-1494
-
(1995)
Science
, vol.270
, pp. 1491-1494
-
-
Kato, S.1
Endoh, H.2
Masuhiro, Y.3
Kitamoto, T.4
Uchiyama, S.5
Sasaki, H.6
Masushige, S.7
Gotoh, Y.8
Nishida, E.9
Kawashima, H.10
Metzger, D.11
Chambon, P.12
-
79
-
-
0026410042
-
Differential DNA-binding abilities of estrogen receptor occupied with two classes of antiestrogens: Studies using human estrogen recpeptor overexpressed in mammalian cells
-
Reese JC, Katzenellenbogen B (1991) Differential DNA-binding abilities of estrogen receptor occupied with two classes of antiestrogens: studies using human estrogen recpeptor overexpressed in mammalian cells. Nucleic Acids Res 19:6595-6602
-
(1991)
Nucleic Acids Res
, vol.19
, pp. 6595-6602
-
-
Reese, J.C.1
Katzenellenbogen, B.2
-
80
-
-
0029044210
-
Effect of antagonists on DNA binding properties of the human estrogen receptor in vitro and in vivo
-
Metzger D, Berry M, Ali S, Chambon P (1995) Effect of antagonists on DNA binding properties of the human estrogen receptor in vitro and in vivo. Mol Endocrinol 9:579-590
-
(1995)
Mol Endocrinol
, vol.9
, pp. 579-590
-
-
Metzger, D.1
Berry, M.2
Ali, S.3
Chambon, P.4
-
81
-
-
0029883292
-
Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines
-
Pink JJ, Jordan VC (1996) Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines. Cancer Res 56:2321-2330
-
(1996)
Cancer Res
, vol.56
, pp. 2321-2330
-
-
Pink, J.J.1
Jordan, V.C.2
-
82
-
-
0025084510
-
Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization
-
Fawell SE, White R, Hoare S, Sydenham M, Page M, Parker MG (1990) Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. Proc Natl Acad Sci 87: 6883-6887
-
(1990)
Proc Natl Acad Sci
, vol.87
, pp. 6883-6887
-
-
Fawell, S.E.1
White, R.2
Hoare, S.3
Sydenham, M.4
Page, M.5
Parker, M.G.6
-
83
-
-
0026341234
-
Antiestrogen can establish nonproductive receptor complexes and alter chromatin structure at target enhancers
-
Pham TA, Elusion JF, Nawaz Z, McDonell D, Tsai M-J, O'Malley BW (1991) Antiestrogen can establish nonproductive receptor complexes and alter chromatin structure at target enhancers. Proc Natl Acad Sci 88:3125-3129
-
(1991)
Proc Natl Acad Sci
, vol.88
, pp. 3125-3129
-
-
Pham, T.A.1
Elusion, J.F.2
Nawaz, Z.3
McDonell, D.4
Tsai, M.-J.5
O'Malley, B.W.6
-
84
-
-
0026410042
-
Differential DNA-binding abilities of estrogen receptor occupied with two classes of antiestrogens: Studies using human estrogen receptor overexpressed in mammalian cells
-
Reese JC, Katzenellenbogen BS (1991) Differential DNA-binding abilities of estrogen receptor occupied with two classes of antiestrogens: studies using human estrogen receptor overexpressed in mammalian cells. Nucleic Acids Res 19: 6595-6602
-
(1991)
Nucleic Acids Res
, vol.19
, pp. 6595-6602
-
-
Reese, J.C.1
Katzenellenbogen, B.S.2
-
85
-
-
0026784736
-
Effects of antioestrogens in the DNA binding activity of estrogen receptors in vitro
-
Arbuckle ND, Dauvois S, Parker MG (1992) Effects of antioestrogens in the DNA binding activity of estrogen receptors in vitro. Nucleic Acids Res 20:3839-3844
-
(1992)
Nucleic Acids Res
, vol.20
, pp. 3839-3844
-
-
Arbuckle, N.D.1
Dauvois, S.2
Parker, M.G.3
-
86
-
-
0026560435
-
Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover
-
Dauvois S, Danielian PS, White R, Parker MG (1992) Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc Natl Acad Sci 89:4037-4041
-
(1992)
Proc Natl Acad Sci
, vol.89
, pp. 4037-4041
-
-
Dauvois, S.1
Danielian, P.S.2
White, R.3
Parker, M.G.4
-
87
-
-
0029916220
-
Short-term effects of pure anti-estrogen ICI 182780 treatment on oestrogen receptor, epidermal growth factor receptor and transforming growth factor-alpha protein expression in human breast cancer
-
McClelland RA, Gee JMW, Francis AB, Robertson JFR, Blamey RW, Wakeling AE, Nicholson RI (1996) Short-term effects of pure anti-estrogen ICI 182780 treatment on oestrogen receptor, epidermal growth factor receptor and transforming growth factor-alpha protein expression in human breast cancer. Eur J Cancer 32A:413-416
-
(1996)
Eur J Cancer
, vol.32 A
, pp. 413-416
-
-
McClelland, R.A.1
Gee, J.M.W.2
Francis, A.B.3
Robertson, J.F.R.4
Blamey, R.W.5
Wakeling, A.E.6
Nicholson, R.I.7
-
88
-
-
0024464667
-
Upregulation of estrogen receptors by nonsteroidal antiestrogens in human breast cancer
-
Kiang DT, Kollander RE, Thomas T, Kennedy BJ (1989) Upregulation of estrogen receptors by nonsteroidal antiestrogens in human breast cancer. Cancer Res 49:5312-5316
-
(1989)
Cancer Res
, vol.49
, pp. 5312-5316
-
-
Kiang, D.T.1
Kollander, R.E.2
Thomas, T.3
Kennedy, B.J.4
-
89
-
-
0027475326
-
Upregulation of estrogen receptor by tamoxifen in human breast cancer
-
Noguchi S, Motomura K, Inaji H, Imaoka S, Koyama H (1993) Upregulation of estrogen receptor by tamoxifen in human breast cancer. Cancer 71:1266-1276
-
(1993)
Cancer
, vol.71
, pp. 1266-1276
-
-
Noguchi, S.1
Motomura, K.2
Inaji, H.3
Imaoka, S.4
Koyama, H.5
-
90
-
-
0028977917
-
Antiestrogenic activity of two 11-estradiol derivatives on MCF-7 breast cancer cells
-
Jin L, Borrás M, Lacroix M, Legros N, Leclercq G (1995) Antiestrogenic activity of two 11-estradiol derivatives on MCF-7 breast cancer cells. Steroids 60:512-518
-
(1995)
Steroids
, vol.60
, pp. 512-518
-
-
Jin, L.1
Borrás, M.2
Lacroix, M.3
Legros, N.4
Leclercq, G.5
-
91
-
-
7144236467
-
Various pure antiestrogens downregulate the HR while partial agonists do not
-
21-24 May 1995, Berlin
-
Parczyk K, Madjno R, Angerer EV, Schneider MR (1995) Various pure antiestrogens downregulate the HR while partial agonists do not. In: 12th International Symposium of the Journal of Steroid Biochemistry and Molecular Biology, 21-24 May 1995, Berlin
-
(1995)
12th International Symposium of the Journal of Steroid Biochemistry and Molecular Biology
-
-
Parczyk, K.1
Madjno, R.2
Angerer, E.V.3
Schneider, M.R.4
-
92
-
-
0027768899
-
The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling
-
Dauvois S, White R, Parker MG (1993) The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci 106:1377-1388
-
(1993)
J Cell Sci
, vol.106
, pp. 1377-1388
-
-
Dauvois, S.1
White, R.2
Parker, M.G.3
-
93
-
-
0029147741
-
Repression of the interleukin-6 promoter by estroizen receptor is mediated by NF-κB and C/EBP
-
Stein B, Yang MX (1995) Repression of the interleukin-6 promoter by estroizen receptor is mediated by NF-κB and C/EBP. Mol Cell Biol 15:4971-4979
-
(1995)
Mol Cell Biol
, vol.15
, pp. 4971-4979
-
-
Stein, B.1
Yang, M.X.2
-
94
-
-
0029889675
-
Involvement of CCA-AT/Enhancer-binding protein and nuclear factor-κB binding sites in interleukin-6 promoter inhibition by estroens
-
Galien R, Evans HF, Garcia T (1996) Involvement of CCA-AT/Enhancer-binding protein and nuclear factor-κB binding sites in interleukin-6 promoter inhibition by estroens. Mol Endocrinol 10:713-722
-
(1996)
Mol Endocrinol
, vol.10
, pp. 713-722
-
-
Galien, R.1
Evans, H.F.2
Garcia, T.3
-
95
-
-
0028901194
-
Tamoxifen activation of the estrogen receptor/AP-1 pathway: Potential origin for the cell specific estrogen like effects of antiestrogens
-
Webb P, Lopez GN, Uht RM, Kushner PJ (1995) Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell specific estrogen like effects of antiestrogens. Mol Endocrinol 9:443-456
-
(1995)
Mol Endocrinol
, vol.9
, pp. 443-456
-
-
Webb, P.1
Lopez, G.N.2
Uht, R.M.3
Kushner, P.J.4
-
96
-
-
0029841146
-
Identification of an estrogen response element activated by metabolites of 17β-estradiol and raloxifen
-
Yang NN, Venugopalan M, Hardikar S, Glasebrook A (1996) Identification of an estrogen response element activated by metabolites of 17β-estradiol and raloxifen. Science 273: 1222-1225
-
(1996)
Science
, vol.273
, pp. 1222-1225
-
-
Yang, N.N.1
Venugopalan, M.2
Hardikar, S.3
Glasebrook, A.4
-
97
-
-
0029075872
-
Comparison of the effects of a steroidal antiestrogen with those of tamoxifen in a model of human breast cancer
-
Osborne CK, Coronado-Heinsohn EB, McCue BL, Wakeling A, Nicholson RI ( 1995) Comparison of the effects of a steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 87:746-750
-
(1995)
J Natl Cancer Inst
, vol.87
, pp. 746-750
-
-
Osborne, C.K.1
Coronado-Heinsohn, E.B.2
McCue, B.L.3
Wakeling, A.4
Nicholson, R.I.5
-
98
-
-
0030017581
-
Properties and mode of action of pure antiestrogens in breast cancer in vitro
-
Nicholson RI, Francis AB, Kyne S, Gee JMW (1996) Properties and mode of action of pure antiestrogens in breast cancer in vitro. Breast 5:175-180
-
(1996)
Breast
, vol.5
, pp. 175-180
-
-
Nicholson, R.I.1
Francis, A.B.2
Kyne, S.3
Gee, J.M.W.4
-
100
-
-
0028919074
-
Cross-resitance and molecular mechanisms in antiestrogen resistance
-
Clarke R, Brünner N (1995) Cross-resitance and molecular mechanisms in antiestrogen resistance. Endocr Rel Cancer 2: 59-72
-
(1995)
Endocr Rel Cancer
, vol.2
, pp. 59-72
-
-
Clarke, R.1
Brünner, N.2
-
101
-
-
0030606494
-
Pure antiestrogens-the most important advance in the endocrine therapy of breast cancer since 1896?
-
Nicholson RI, Gee JMW, Bryant S, Francis AB, McClelland RA, Knowlden J, Wakeling AE, Osborne CK (1996) Pure antiestrogens-the most important advance in the endocrine therapy of breast cancer since 1896? Ann NY Acad Sci 784: 325-335
-
(1996)
Ann NY Acad Sci
, vol.784
, pp. 325-335
-
-
Nicholson, R.I.1
Gee, J.M.W.2
Bryant, S.3
Francis, A.B.4
McClelland, R.A.5
Knowlden, J.6
Wakeling, A.E.7
Osborne, C.K.8
-
103
-
-
84928580276
-
Studies on prostatic cancer: The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate
-
Huggins C, Hodges CV (1941) Studies on prostatic cancer: the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1:293-297
-
(1941)
Cancer Res
, vol.1
, pp. 293-297
-
-
Huggins, C.1
Hodges, C.V.2
-
104
-
-
0014088849
-
Treatment and survival of patients with cancer of the prostate
-
Veterans Administration Co-operative Urological Research Group (1967) Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 124:1010-1017
-
(1967)
Surg Gynecol Obstet
, vol.124
, pp. 1010-1017
-
-
-
105
-
-
0021721387
-
Leuprolide versus diethylstilbesterol for metastatic prostate cancer
-
The Leuprolide Study Group (1984) Leuprolide versus diethylstilbesterol for metastatic prostate cancer. N Engl J Med 311:1281-1286
-
(1984)
N Engl J Med
, vol.311
, pp. 1281-1286
-
-
-
106
-
-
0019977879
-
From contraception to cancer: A review of the therapeutic applications of LHRH analogs as antitumor agents
-
Corbin A (1982) From contraception to cancer: a review of the therapeutic applications of LHRH analogs as antitumor agents. Yale J Biol Med 55:27-47
-
(1982)
Yale J Biol Med
, vol.55
, pp. 27-47
-
-
Corbin, A.1
-
107
-
-
0023681542
-
Androgenic activity of dehydroepiandrosterone and androstenedione in the rat ventral prostate
-
Labrie C, Belanger A, Labrie F (1988) Androgenic activity of dehydroepiandrosterone and androstenedione in the rat ventral prostate. Endocrinology, 123:1412-1417
-
(1988)
Endocrinology
, vol.123
, pp. 1412-1417
-
-
Labrie, C.1
Belanger, A.2
Labrie, F.3
-
108
-
-
0024401194
-
Stimulation of androgen-dependent gene expression by the adrenal precursors dehydroepiandrosterone and androstenedione in the rat ventral prostate
-
Labrie C, Simard J, Zhao HF, Belanyer A, Pelletier G, Labrie F (1989) Stimulation of androgen-dependent gene expression by the adrenal precursors dehydroepiandrosterone and androstenedione in the rat ventral prostate. Endocr Soc 124:2745-2754
-
(1989)
Endocr Soc
, vol.124
, pp. 2745-2754
-
-
Labrie, C.1
Simard, J.2
Zhao, H.F.3
Belanyer, A.4
Pelletier, G.5
Labrie, F.6
-
109
-
-
0027879412
-
Science behind total androgen blockade: From gene to combination therapy
-
Labrie F, Belanger A, Dupont A, Luu The V, Simard J, Labrie C (1993) Science behind total androgen blockade: from gene to combination therapy. Clin Invest Med 16:475-492
-
(1993)
Clin Invest Med
, vol.16
, pp. 475-492
-
-
Labrie, F.1
Belanger, A.2
Dupont, A.3
Luu The, V.4
Simard, J.5
Labrie, C.6
-
110
-
-
0027523389
-
Combination therapy for prostate cancer. Endocrine and biologic basis of its choice as new standard first-line therapy
-
Labrie F, Belanger A, Simard J, Labrie C, Dupont A (1993) Combination therapy for prostate cancer. Endocrine and biologic basis of its choice as new standard first-line therapy. Cancer 71:1059-1067
-
(1993)
Cancer
, vol.71
, pp. 1059-1067
-
-
Labrie, F.1
Belanger, A.2
Simard, J.3
Labrie, C.4
Dupont, A.5
-
111
-
-
0023064446
-
New concepts on the androgen sensitivity of prostate cancer
-
Labrie F, Lurthy I, Veilleux R, Simard J, Belanger A, Dupont A (1987) New concepts on the androgen sensitivity of prostate cancer. Prog Clin Biol Res 243A: 145-172
-
(1987)
Prog Clin Biol Res
, vol.243 A
, pp. 145-172
-
-
Labrie, F.1
Lurthy, I.2
Veilleux, R.3
Simard, J.4
Belanger, A.5
Dupont, A.6
-
112
-
-
0022405204
-
Combination therapy with flutumide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: A marked improvement in response and survival
-
Labrie F, Dupont A, Belanger A, Giguere M, Lacoursiere Y, Emond J, Monfette G, Bergeron V (1985) Combination therapy with flutumide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in response and survival. J Steroid Biochem 23:833-841
-
(1985)
J Steroid Biochem
, vol.23
, pp. 833-841
-
-
Labrie, F.1
Dupont, A.2
Belanger, A.3
Giguere, M.4
Lacoursiere, Y.5
Emond, J.6
Monfette, G.7
Bergeron, V.8
-
113
-
-
0021803140
-
Long term treatment with luteinising hormone releasing hormone agonists and maintenance of serum testosterone to castration concentrations
-
Labrie F, Dupont A, Belanger A, Lachance R, Giguere M (1985) Long term treatment with luteinising hormone releasing hormone agonists and maintenance of serum testosterone to castration concentrations. BMJ 291:369-370
-
(1985)
BMJ
, vol.291
, pp. 369-370
-
-
Labrie, F.1
Dupont, A.2
Belanger, A.3
Lachance, R.4
Giguere, M.5
-
114
-
-
0025102970
-
Leuprolide with and without flutamide in advanced prostate cancer
-
Crawford ED, Blumenstein BA, Goodman PJ, Davis MA, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA (1990) Leuprolide with and without flutamide in advanced prostate cancer. Cancer 66:1039-1044
-
(1990)
Cancer
, vol.66
, pp. 1039-1044
-
-
Crawford, E.D.1
Blumenstein, B.A.2
Goodman, P.J.3
Davis, M.A.4
Eisenberger, M.A.5
McLeod, D.G.6
Spaulding, J.T.7
Benson, R.8
Dorr, F.A.9
-
115
-
-
0025667031
-
Combination studies with leuprolide
-
Crawford ED (1990) Combination studies with leuprolide. Eur Urol 3:30-33
-
(1990)
Eur Urol
, vol.3
, pp. 30-33
-
-
Crawford, E.D.1
-
116
-
-
0029103141
-
Maximum androgen blockade in advanced prostate cancer: An overview of 22 randomised trials with 3283 deaths in 5710 patients
-
Prostate Cancer Trialists' Group (1995) Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet 346:265-269
-
(1995)
Lancet
, vol.346
, pp. 265-269
-
-
-
117
-
-
0025806437
-
Androgen receptors in endocrine therapy-resistant human prostate cancer
-
Van der Kwast T, Schalken J, Ruizeveld de Winter J, Van Vroonhoven C, Mulder E, Boersma W, Trapman J (1991) Androgen receptors in endocrine therapy-resistant human prostate cancer. Int J Cancer 48:189
-
(1991)
Int J Cancer
, vol.48
, pp. 189
-
-
Van Der Kwast, T.1
Schalken, J.2
Ruizeveld De Winter, J.3
Van Vroonhoven, C.4
Mulder, E.5
Boersma, W.6
Trapman, J.7
-
118
-
-
0025819482
-
Immunohistochemical study of androgen receptors in metastatic prostate cancer - Comparison of receptor content and response to hormonal therapy
-
Sadi MV, Walsh PC, Barrack ER (1991) Immunohistochemical study of androgen receptors in metastatic prostate cancer - comparison of receptor content and response to hormonal therapy. Cancer 67:3057-3064
-
(1991)
Cancer
, vol.67
, pp. 3057-3064
-
-
Sadi, M.V.1
Walsh, P.C.2
Barrack, E.R.3
-
119
-
-
0027536495
-
Image analysis of androgen receptor immunostaining in metastatic prostate cancer: Heterogeneity as a predictor of response to hormonal therapy
-
Sadi MV, Barrack ER (1992) Image analysis of androgen receptor immunostaining in metastatic prostate cancer: heterogeneity as a predictor of response to hormonal therapy. Cancer 71:2574-2580
-
(1992)
Cancer
, vol.71
, pp. 2574-2580
-
-
Sadi, M.V.1
Barrack, E.R.2
-
120
-
-
0025214385
-
Androgen receptor heterogeneity in human prostatic carcinomas visualized by immunohistochemistry
-
Ruizveld de Vinter JA, Trapman J, Brinkmann AO, Boersma WJA, Mulder E, Schroeder FH, Claassen E, and Van der Kwast TH (1990) Androgen receptor heterogeneity in human prostatic carcinomas visualized by immunohistochemistry. J Pathol 161:329-332
-
(1990)
J Pathol
, vol.161
, pp. 329-332
-
-
Ruizveld De Vinter, J.A.1
Trapman, J.2
Brinkmann, A.O.3
Boersma, W.J.A.4
Mulder, E.5
Schroeder, F.H.6
Claassen, E.7
Van Der Kwast, T.H.8
-
121
-
-
0030024517
-
Androgen receptor status of lymph node metastases from prostatic carcinoma
-
Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H, Hittmair A (1996) Androgen receptor status of lymph node metastases from prostatic carcinoma. Prostate 28:129-135
-
(1996)
Prostate
, vol.28
, pp. 129-135
-
-
Hobisch, A.1
Culig, Z.2
Radmayr, C.3
Bartsch, G.4
Klocker, H.5
Hittmair, A.6
-
122
-
-
0029072101
-
Distant metastases from prostatic carcinoma express androgen receptor protein
-
Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H, Hittmair A (1995) Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res 55:3068-3072
-
(1995)
Cancer Res
, vol.55
, pp. 3068-3072
-
-
Hobisch, A.1
Culig, Z.2
Radmayr, C.3
Bartsch, G.4
Klocker, H.5
Hittmair, A.6
-
123
-
-
0028823124
-
Analysis of genetic changes underlying local recurrence of prostate carcinoma during androgen deprivation therapy
-
Koivisto P, Hyytinen E, Palmberg C, Tammela T, Visakorpi T, Isola J, Kallioniemi OP (1995) Analysis of genetic changes underlying local recurrence of prostate carcinoma during androgen deprivation therapy. Am J Pathol 147:1608-1614
-
(1995)
Am J Pathol
, vol.147
, pp. 1608-1614
-
-
Koivisto, P.1
Hyytinen, E.2
Palmberg, C.3
Tammela, T.4
Visakorpi, T.5
Isola, J.6
Kallioniemi, O.P.7
-
124
-
-
0028944138
-
In vivo amplification of the androgen receptor gene and progression of human prostate cancer
-
Visakorpi T, Hyytinen E, Hoivisto P, Tanner M, Keinanen R, Palmberg C, Palotie A, Tammela T, Isola J, Kallioniemi OP (1995) In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nature Genet 4:401-406
-
(1995)
Nature Genet
, vol.4
, pp. 401-406
-
-
Visakorpi, T.1
Hyytinen, E.2
Hoivisto, P.3
Tanner, M.4
Keinanen, R.5
Palmberg, C.6
Palotie, A.7
Tammela, T.8
Isola, J.9
Kallioniemi, O.P.10
-
125
-
-
0028220323
-
Increased androgen receptor activity and altered c-myc expression in prostate cancer cells alter long-term androgen deprivation
-
Kokontis J, Takakura K, Hay N, Liao S (1994) Increased androgen receptor activity and altered c-myc expression in prostate cancer cells alter long-term androgen deprivation. Cancer Res 54:1566-1573
-
(1994)
Cancer Res
, vol.54
, pp. 1566-1573
-
-
Kokontis, J.1
Takakura, K.2
Hay, N.3
Liao, S.4
-
126
-
-
0028179885
-
24→18) in the androgen receptor gene in human prostate cancer
-
24→18) in the androgen receptor gene in human prostate cancer. Biochem Biophys Res Commun 198:74-80
-
(1994)
Biochem Biophys Res Commun
, vol.198
, pp. 74-80
-
-
Schoenberg, M.P.1
Hakimi, J.M.2
Wang, S.3
Bora, G.S.4
Epstein, J.I.5
Fischbeck, K.H.6
Issac, W.B.7
Walsch, P.C.8
Barrack, E.R.9
-
127
-
-
0027732019
-
Androgen receptor gene mutations in human prostate cancer
-
Suzuki H, Sato N, Watabe Y, Masai M, Seino S, Shimazaki J (1993) Androgen receptor gene mutations in human prostate cancer. J Steroid Biochem Molec Biol 46:759-765
-
(1993)
J Steroid Biochem Molec Biol
, vol.46
, pp. 759-765
-
-
Suzuki, H.1
Sato, N.2
Watabe, Y.3
Masai, M.4
Seino, S.5
Shimazaki, J.6
-
128
-
-
0029011116
-
Mutation of the androgen receptor gene in metastatic androgen-independent prostate cancer
-
Taplin M-E, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP (1995) Mutation of the androgen receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332:1393-1398
-
(1995)
N Engl J Med
, vol.332
, pp. 1393-1398
-
-
Taplin, M.-E.1
Bubley, G.J.2
Shuster, T.D.3
Frantz, M.E.4
Spooner, A.E.5
Ogata, G.K.6
Keer, H.N.7
Balk, S.P.8
-
129
-
-
0029915052
-
Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence
-
Tilley WD, Buchanan G, Hickey TE, Bentel JM (1996) Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res 2:277-285
-
(1996)
Clin Cancer Res
, vol.2
, pp. 277-285
-
-
Tilley, W.D.1
Buchanan, G.2
Hickey, T.E.3
Bentel, J.M.4
-
130
-
-
85003173512
-
Mutant receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone
-
Culig Z, Hobisch A, Cronauer MV, Cato ACB, Hittmair A, Radmayr C, Eberle J, Bartsch G, Klocker H (1993) Mutant receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol. Endocrinol 7:1541-1550
-
(1993)
Mol. Endocrinol
, vol.7
, pp. 1541-1550
-
-
Culig, Z.1
Hobisch, A.2
Cronauer, M.V.3
Cato, A.C.B.4
Hittmair, A.5
Radmayr, C.6
Eberle, J.7
Bartsch, G.8
Klocker, H.9
-
131
-
-
0026652555
-
Androgen-receptor gene mutations in human prostate cancer
-
Newmark JR, Hardy DO, Tonb DC, Carter BS, Epstein JI, Issac WB, Brown TR, Barrack ER (1992) Androgen-receptor gene mutations in human prostate cancer. Proc Natl Acad Sci USA 89:6319-6323
-
(1992)
Proc Natl Acad Sci USA
, vol.89
, pp. 6319-6323
-
-
Newmark, J.R.1
Hardy, D.O.2
Tonb, D.C.3
Carter, B.S.4
Epstein, J.I.5
Issac, W.B.6
Brown, T.R.7
Barrack, E.R.8
-
132
-
-
0028278076
-
Frequent detection of codon 877 mutation in the androgen-receptor gene inadvanced prostate cancers
-
Gaddipati JP, McLeod DG, Heidenberg HB, Sesterhenn IA, Finger MJ, Moul JW, Srivastava S (1994) Frequent detection of codon 877 mutation in the androgen-receptor gene inadvanced prostate cancers. Cancer Res 54:2861-2864
-
(1994)
Cancer Res
, vol.54
, pp. 2861-2864
-
-
Gaddipati, J.P.1
McLeod, D.G.2
Heidenberg, H.B.3
Sesterhenn, I.A.4
Finger, M.J.5
Moul, J.W.6
Srivastava, S.7
-
133
-
-
0025644325
-
A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens
-
Veldscholte J, Ris-Stalpers C, Kuiper GG, Jenster G, Berrevoets C, Claassen E, Van Rooij HC, Trapman J, Brinkmann AO, Mulder E (1990) A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 173:534-540
-
(1990)
Biochem Biophys Res Commun
, vol.173
, pp. 534-540
-
-
Veldscholte, J.1
Ris-Stalpers, C.2
Kuiper, G.G.3
Jenster, G.4
Berrevoets, C.5
Claassen, E.6
Van Rooij, H.C.7
Trapman, J.8
Brinkmann, A.O.9
Mulder, E.10
-
134
-
-
0027427321
-
Threonine on amino acid position 868 in the human androgen receptor is essential for androgen binding specificity and functional activity
-
Ris-Stalpers C, Verleun-Mooijman MCT, Trapman J, Brinkmann AO (1993) Threonine on amino acid position 868 in the human androgen receptor is essential for androgen binding specificity and functional activity. Bioxhem Biophys Res Commun 196:173-180
-
(1993)
Bioxhem Biophys Res Commun
, vol.196
, pp. 173-180
-
-
Ris-Stalpers, C.1
Verleun-Mooijman, M.C.T.2
Trapman, J.3
Brinkmann, A.O.4
-
135
-
-
0028804247
-
Mutant androgen receptors in prostatic tumours distinguish between amino acid-sequence requirements for transactivation and ligand binding
-
Peterziel H, Culig Z, Stober J, Hobisch A, Radmayr C, Bartsch G, Klocker H, Cato ACB (1995) Mutant androgen receptors in prostatic tumours distinguish between amino acid-sequence requirements for transactivation and ligand binding. Int J Cancer 63:544-550
-
(1995)
Int J Cancer
, vol.63
, pp. 544-550
-
-
Peterziel, H.1
Culig, Z.2
Stober, J.3
Hobisch, A.4
Radmayr, C.5
Bartsch, G.6
Klocker, H.7
Cato, A.C.B.8
-
136
-
-
0029643780
-
Crystal structure of the RARγ-ligand binding domain bound to all-trans retinoic acid
-
Renaud J-P, Rochel N, Ruff M, Vivat V, Chambon P, Gronemeyer H, Moras, D (1995) Crystal structure of the RARγ-ligand binding domain bound to all-trans retinoic acid. Nature 378:681-689
-
(1995)
Nature
, vol.378
, pp. 681-689
-
-
Renaud, J.-P.1
Rochel, N.2
Ruff, M.3
Vivat, V.4
Chambon, P.5
Gronemeyer, H.6
Moras, D.7
-
137
-
-
0030056997
-
A canonical structure for the ligand-binding domain of nuclear receptor
-
Wurtz J-M, Bourguet W, Renaud J-P, Vivat V, Chambon P, Moras D, Gronemeyer H (1996) A canonical structure for the ligand-binding domain of nuclear receptor. Nat Struct Biol 3: 87-94
-
(1996)
Nat Struct Biol
, vol.3
, pp. 87-94
-
-
Wurtz, J.-M.1
Bourguet, W.2
Renaud, J.-P.3
Vivat, V.4
Chambon, P.5
Moras, D.6
Gronemeyer, H.7
-
138
-
-
0029012163
-
Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-α
-
Bourguet W, Ruff M, Chambon P, Gronemeyer H, Moras, D (1995) Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-α. Nature 375:377-382
-
(1995)
Nature
, vol.375
, pp. 377-382
-
-
Bourguet, W.1
Ruff, M.2
Chambon, P.3
Gronemeyer, H.4
Moras, D.5
-
139
-
-
0029643769
-
A structural role of hormone in the thyroid hormone receptor
-
Wagner RL, Apriletti JW, McGrath ME, West BL, Baxter JD, Fletterick RJ (1995) A structural role of hormone in the thyroid hormone receptor. Nature 378:690-697
-
(1995)
Nature
, vol.378
, pp. 690-697
-
-
Wagner, R.L.1
Apriletti, J.W.2
McGrath, M.E.3
West, B.L.4
Baxter, J.D.5
Fletterick, R.J.6
-
140
-
-
0027477695
-
Prostate specific antigen decline after antiandrogen withdrawal: The flutamide withdrawal syndrome
-
Kelly WK, Scher HI (1993) Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol 149:607-609
-
(1993)
J Urol
, vol.149
, pp. 607-609
-
-
Kelly, W.K.1
Scher, H.I.2
-
141
-
-
0027203411
-
Flutamide withdrawal syndrome: Its impact on clinical trials in hormone-refractory prostate cancer
-
Scher HI, Kelly WK (1993) Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 11:1566-1572
-
(1993)
J Clin Oncol
, vol.11
, pp. 1566-1572
-
-
Scher, H.I.1
Kelly, W.K.2
-
142
-
-
0028089068
-
Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer
-
published erratum appears in J Natl Cancer Inst 86:463
-
Sartor O, Cooper M, Weinberger M, Headlee D, Thibault A, Tompkins A, Steinberg S, Figg WD, Linehan WM, Myers CE (1994) Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer. J Natl Cancer Inst 86:222-227 (published erratum appears in J Natl Cancer Inst 86:463)
-
(1994)
J Natl Cancer Inst
, vol.86
, pp. 222-227
-
-
Sartor, O.1
Cooper, M.2
Weinberger, M.3
Headlee, D.4
Thibault, A.5
Tompkins, A.6
Steinberg, S.7
Figg, W.D.8
Linehan, W.M.9
Myers, C.E.10
-
143
-
-
0028907804
-
Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer
-
Figg WD, Sartor O, Cooper MR, Thibault A, Bergan RC, Dawson N, Reed E, Myers CE (1995) Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer. Am J Med 98:412-114
-
(1995)
Am J Med
, vol.98
, pp. 412-1114
-
-
Figg, W.D.1
Sartor, O.2
Cooper, M.R.3
Thibault, A.4
Bergan, R.C.5
Dawson, N.6
Reed, E.7
Myers, C.E.8
-
144
-
-
0027249588
-
Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy
-
Dupont A, Gomez JL, Cusan L, Koutsilieris M, Labrie F (1993) Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J Urol 150:908-913
-
(1993)
J Urol
, vol.150
, pp. 908-913
-
-
Dupont, A.1
Gomez, J.L.2
Cusan, L.3
Koutsilieris, M.4
Labrie, F.5
-
145
-
-
0028998340
-
Molecular implications of the antiandrogen withdrawal syndrome
-
Moul JW, Srivastava S, McLeod DG (1995) Molecular implications of the antiandrogen withdrawal syndrome. Semin Urol 13:157-163
-
(1995)
Semin Urol
, vol.13
, pp. 157-163
-
-
Moul, J.W.1
Srivastava, S.2
McLeod, D.G.3
-
146
-
-
0028256111
-
Prostate-specific antigen decline after casodex withdrawal: Evidence for an antiandrogen withdrawal syndrome
-
Small EJ, Carroll PR (1994) Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. Urology 43:408-410
-
(1994)
Urology
, vol.43
, pp. 408-410
-
-
Small, E.J.1
Carroll, P.R.2
-
147
-
-
0028858232
-
Antiandrogen withdrawal syndrome in prostate cancer after treatment with steroidal antiandrogen chlormadinone acetate
-
Akakura K, Akimoto S, Ohki T, Shimazaki J (1995) Antiandrogen withdrawal syndrome in prostate cancer after treatment with steroidal antiandrogen chlormadinone acetate. Urology 45:700-704
-
(1995)
Urology
, vol.45
, pp. 700-704
-
-
Akakura, K.1
Akimoto, S.2
Ohki, T.3
Shimazaki, J.4
-
148
-
-
0029007052
-
Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: Expansion of the antiandrogen withdrawal syndrome
-
Dawson NA, McLeod DG (1995) Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome. J Urol 153:1946-1947
-
(1995)
J Urol
, vol.153
, pp. 1946-1947
-
-
Dawson, N.A.1
McLeod, D.G.2
-
149
-
-
0028609997
-
Tamoxifen withdrawal responses-chance observations or clinical clues to antioestrogen resistance
-
DeFriend DJ, Howell A (1994) Tamoxifen withdrawal responses-chance observations or clinical clues to antioestrogen resistance. Breast 3:199-201
-
(1994)
Breast
, vol.3
, pp. 199-201
-
-
DeFriend, D.J.1
Howell, A.2
-
150
-
-
0027416692
-
Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen
-
Akakura K, Bruchovsky N, Goldenberg SL, Rennie PS, Buckley AR, Sullivan LD (1993) Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen. Cancer 71:2782-2790
-
(1993)
Cancer
, vol.71
, pp. 2782-2790
-
-
Akakura, K.1
Bruchovsky, N.2
Goldenberg, S.L.3
Rennie, P.S.4
Buckley, A.R.5
Sullivan, L.D.6
-
151
-
-
0029691526
-
Control of tumor progression by maintenance of apoptosis
-
Bruchovsky N, Snoek R, Rennie PS, Akakura K, Goldenberg LS, Gleave M (1996) Control of tumor progression by maintenance of apoptosis. Prostate Suppl 6:13-21
-
(1996)
Prostate Suppl
, vol.6
, pp. 13-21
-
-
Bruchovsky, N.1
Snoek, R.2
Rennie, P.S.3
Akakura, K.4
Goldenberg, L.S.5
Gleave, M.6
-
152
-
-
0029050259
-
Theoretical considerations and initial clinical results of intermittent hormone treatment of patients with advanced prostatic carcinoma
-
Bruchovsky N, Goldenberg SL, Rennie PS, Gleave M (1995) Theoretical considerations and initial clinical results of intermittent hormone treatment of patients with advanced prostatic carcinoma. Urologe A34:389-392
-
(1995)
Urologe
, vol.A34
, pp. 389-392
-
-
Bruchovsky, N.1
Goldenberg, S.L.2
Rennie, P.S.3
Gleave, M.4
-
153
-
-
0029068688
-
Recent multicenter study protocols in the USA for patients with metastatic prostatic carcinoma
-
DeAntoni E, Crawford ED (1995) Recent multicenter study protocols in the USA for patients with metastatic prostatic carcinoma. Urologe A34:382-388
-
(1995)
Urologe
, vol.A34
, pp. 382-388
-
-
DeAntoni, E.1
Crawford, E.D.2
-
154
-
-
0029591491
-
Defining the role of antiandrogens in the treatment of prostate cancer
-
McLeod DG, Kolvenbag GJ (1996) Defining the role of antiandrogens in the treatment of prostate cancer. Urology 47:85-89
-
(1996)
Urology
, vol.47
, pp. 85-89
-
-
McLeod, D.G.1
Kolvenbag, G.J.2
-
155
-
-
0028948168
-
Prevalence of androgen receptor gene mutation in latent prostatic carcinomas from Japanese men
-
Takahashi H, Furusato M, Allsbrook Jr WC, Nishii H, Wakui S, Barrett JC, Boyd J (1995) Prevalence of androgen receptor gene mutation in latent prostatic carcinomas from Japanese men. Cancer Res 55:1621-1624
-
(1995)
Cancer Res
, vol.55
, pp. 1621-1624
-
-
Takahashi, H.1
Furusato, M.2
Allsbrook Jr., W.C.3
Nishii, H.4
Wakui, S.5
Barrett, J.C.6
Boyd, J.7
-
156
-
-
0021931574
-
Endometrial and pituiary responses to the sterodal antiprogestin R7486 in postmeriopansal women
-
Gravanis A, Schaison G, George M (1985) Endometrial and pituiary responses to the sterodal antiprogestin R7486 in postmeriopansal women. J Clin Endocr Metab 60:156-63
-
(1985)
J Clin Endocr Metab
, vol.60
, pp. 156-163
-
-
Gravanis, A.1
Schaison, G.2
George, M.3
-
157
-
-
0030272097
-
Acquired estrogen independence and antiestrogen resistance in breast cancer. Estrogen receptor driven phenotypes?
-
Clarke R, Brünner N (1996) Acquired estrogen independence and antiestrogen resistance in breast cancer. Estrogen receptor driven phenotypes? Trends Endocrinol Metab 7:291-301
-
(1996)
Trends Endocrinol Metab
, vol.7
, pp. 291-301
-
-
Clarke, R.1
Brünner, N.2
-
158
-
-
0030793285
-
(S)-(+)-4-[7-(2,2-Dimethyl-1-oxopropoxy)-4-methyl-2-]4-[2-(1-piperidinyl) -ethoxy[phenyl]-2H-1-benzopyran-3-yl]-phenyl 2,2-dimethylpropanoate (EM-800): A highly potent, specific, and orally active nonsteroidal antiestrogen
-
Gauthier S, Caron B, Cloutier J, Dory YL, Favre A, Larouche D, Mailhot J, Quellet C, Schwerdtfeger A, Leblanc G, Martel C, Simard J, Merand Y, Belanger A, Labrie C, Labrie F (1997) (S)-(+)-4-[7-(2,2-Dimethyl-1-oxopropoxy)-4-methyl-2-]4-[2-(1-piperidinyl)- ethoxy[phenyl]-2H-1-benzopyran-3-yl]-phenyl 2,2-dimethylpropanoate (EM-800): a highly potent, specific, and orally active nonsteroidal antiestrogen. J Med Chem 40:2117-2122
-
(1997)
J Med Chem
, vol.40
, pp. 2117-2122
-
-
Gauthier, S.1
Caron, B.2
Cloutier, J.3
Dory, Y.L.4
Favre, A.5
Larouche, D.6
Mailhot, J.7
Quellet, C.8
Schwerdtfeger, A.9
Leblanc, G.10
Martel, C.11
Simard, J.12
Merand, Y.13
Belanger, A.14
Labrie, C.15
Labrie, F.16
-
159
-
-
0030968438
-
CDK-independent activation of estrogen receptor by cyclin di
-
Zwijsen RML. Wientjens E, Klompmaker R, Van de Sman J, Bernards R, Michalides RJAM (1997) CDK-independent activation of estrogen receptor by cyclin DI. Cell 88: 405-415
-
(1997)
Cell
, vol.88
, pp. 405-415
-
-
Zwijsen, R.M.L.1
Wientjens, E.2
Klompmaker, R.3
Van De Sman, J.4
Bernards, R.5
Michalides, R.J.A.M.6
-
160
-
-
0030579801
-
Cloning of a novel estrogen receptor expresed in rat prostate and ovary
-
Kuiper GJM, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson J-Å (1996) Cloning of a novel estrogen receptor expresed in rat prostate and ovary. Proc Natl Acad Sci 93:5925-5930
-
(1996)
Proc Natl Acad Sci
, vol.93
, pp. 5925-5930
-
-
Kuiper, G.J.M.1
Enmark, E.2
Pelto-Huikko, M.3
Nilsson, S.4
Gustafsson, J.-Å.5
-
161
-
-
0030593681
-
ERβ: Identification and characterization of a novel estrogen receptor
-
Mosselman S, Polman J, Dijkema R (1996) ERβ: identification and characterization of a novel estrogen receptor. FEBS Lett 392:49-53
-
(1996)
FEBS Lett
, vol.392
, pp. 49-53
-
-
Mosselman, S.1
Polman, J.2
Dijkema, R.3
-
162
-
-
0028264276
-
1-Carbamoylalkyl-2-phenylindoles: Relationship between side chain structure and estrogen antagonism
-
Von Angerer E, Biberger C, Holler E, Koop R, Leichtl S (1994) 1-Carbamoylalkyl-2-phenylindoles: relationship between side chain structure and estrogen antagonism. J Steroid Biochem Mol Biol 49:51-62
-
(1994)
J Steroid Biochem Mol Biol
, vol.49
, pp. 51-62
-
-
Von Angerer, E.1
Biberger, C.2
Holler, E.3
Koop, R.4
Leichtl, S.5
-
163
-
-
84914786481
-
11β-Aminoalkoxyphenylestradiols, a new series of potent antiestrogens
-
(abstract 34P). Las Palmas
-
Nédélec L, Bouton MM, Nique F, Teutsch G, Van de Velde P, Philibert D (1989) 11β-Aminoalkoxyphenylestradiols, a new series of potent antiestrogens (abstract 34P). In: 9th International Symosium of J Steroid Biochem, Las Palmas
-
(1989)
9th International Symosium of J Steroid Biochem
-
-
Nédélec, L.1
Bouton, M.M.2
Nique, F.3
Teutsch, G.4
Van De Velde, P.5
Philibert, D.6
-
164
-
-
0029740105
-
Nuclear receptor coactivators and corepressors
-
Horwitz KB, Jackson TA, Bain DL, Richer JK, Takimoto GS, Lung L (1996) Nuclear receptor coactivators and corepressors. Mol Endocrinol 10:1167-1177
-
(1996)
Mol Endocrinol
, vol.10
, pp. 1167-1177
-
-
Horwitz, K.B.1
Jackson, T.A.2
Bain, D.L.3
Richer, J.K.4
Takimoto, G.S.5
Lung, L.6
-
165
-
-
0030946198
-
Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen. 4-hydroxytamoxifen
-
Smith CL, Nawaz Z, O'Malley BW (1997) Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen. 4-hydroxytamoxifen. Mol Endocrinol 11:657-666
-
(1997)
Mol Endocrinol
, vol.11
, pp. 657-666
-
-
Smith, C.L.1
Nawaz, Z.2
O'Malley, B.W.3
-
166
-
-
0030998328
-
The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coaetivalor L7/SPA and the compressors N-CoR and SMRT
-
Jackson TA, Richer JK, Bain DL, Takimoto GS, Tung L, Horwitz, KB (1997) The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coaetivalor L7/SPA and the compressors N-CoR and SMRT. Mol Endocrinol 11:693-705
-
(1997)
Mol Endocrinol
, vol.11
, pp. 693-705
-
-
Jackson, T.A.1
Richer, J.K.2
Bain, D.L.3
Takimoto, G.S.4
Tung, L.5
Horwitz, K.B.6
|